CN1049119C - Preparation method of anti-hepatitis B placental transfer factor injection - Google Patents
Preparation method of anti-hepatitis B placental transfer factor injection Download PDFInfo
- Publication number
- CN1049119C CN1049119C CN93100357A CN93100357A CN1049119C CN 1049119 C CN1049119 C CN 1049119C CN 93100357 A CN93100357 A CN 93100357A CN 93100357 A CN93100357 A CN 93100357A CN 1049119 C CN1049119 C CN 1049119C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- homogenate
- preparation
- transfer factor
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010074506 Transfer Factor Proteins 0.000 title claims abstract description 13
- 238000002347 injection Methods 0.000 title claims abstract description 10
- 239000007924 injection Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000003169 placental effect Effects 0.000 title claims description 8
- 208000002672 hepatitis B Diseases 0.000 title abstract description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 18
- 210000002826 placenta Anatomy 0.000 claims abstract description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 12
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 8
- 102000036639 antigens Human genes 0.000 claims abstract description 8
- 108091007433 antigens Proteins 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims abstract description 4
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 4
- 239000012154 double-distilled water Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 description 11
- 231100000283 hepatitis Toxicity 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 3
- 230000005965 immune activity Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 206010059193 Acute hepatitis B Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a method for preparing anti-hepatitis B placenta specific transfer factor injection by taking placenta with hepatitis B virus markers of positive antigen body, negative antigen body and positive antibody body as raw materials and through the steps of grinding, adding sodium chloride solution, two-step inactivation (heating for 5-15 hours at 56 ℃, adding formaldehyde), filtration, ultrafiltration and the like. The preparation prepared by the method not only has nonspecific immunocompetence, but also has definite specific immunocompetence to hepatitis B virus, has no toxic and side effects after long-term use, and has good effect on treating various liver diseases.
Description
The present invention relates to a kind of preparation method of anti-B-hepatitis placental transfer factor injection.
All there is the low phenomenon of cellular immune function in present known acute or chronic hepatitis B patient, thus the acute hepatitis B patient after being ill minority can not remove the body inner virus smoothly, transfer to chronic; Chronic hepatitis (chronic persisting type, chronic active type, the early stage hepatitis interstitialis chronica of chronic active hepatitis body and hepatitis interstitialis chronica) is then because of immunologic hypofunction, long-term existence hepatitis B virus, hepatic tissue constantly are subjected to immunoreation destruction in the body, slowly change early stage hepatitis interstitialis chronica over to by chronic liver-fire, transfer hepatitis interstitialis chronica again to, even on the hepatitis interstitialis chronica basis, occur canceration of hepatic cell again.Therefore, immunomodulator on probation improves sick body immunologic function, particularly cellular immune function, and the cloudy commentaries on classics of hepatitis B virus in pathological changes recovery and the blood is to inquire into emphasis after the seventies in the promotion liver.In existing various immunomodulators,, can not prove that hepatitis B virus is had clear and definite specific immune activity, thereby therapeutic effect is also relatively poor though how provable have the nonspecific immunity activity of degree varies to human body.Therefore, the specific immunity regulator of treatment hepatitis B virus infection is the emphasis of research and inquirement in recent years always.
Transfer factor is one of immunomodulator, proposes till now from the beginning of the fifties, and is external still with the cell of human body, particularly lymphocyte, costs an arm and a leg because material is rare for extracting raw material, lack the clear and definite specific activity of hepatitis B virus especially, the result has limited and has promoted the use of.Large animal corresponding organ tissue on probation is made raw material or earlier to antigen injection sensitization, is prepared common transfer factor (non-specific) or specific transfer factor, except that having above-mentioned shortcoming equally, the different problem of people and animals is arranged still.Though more domestic in recent years reports that relevant extraction transfer factors from Placenta Hominis are arranged, as: work such as Guo Jingang " extraction of placental transfer factor, physics and chemistry method and clinical practice " (Jiang Sushengjin county Technology Committee data 1984/10), Liu Yue newly waits work " a kind of preparation and research of new immunomodulator-placenta factor " (Chinese Journal of Immunology 1985,1 (5)), but they are common Placenta Hominis by used Placenta Hominis, lack the clear and definite specific immune activity of hepatitis B virus.
The objective of the invention is to develop a kind of Placenta Hominis with hepatitis B virus infection sensitization is raw material, with the method for improved extraction transfer factor injection, overcomes above-mentioned weak point, preparation anti-hepatitis B specific transfer factor injection.
The object of the present invention is achieved like this: selecting hepatitis b virus marker antigen, antibody positive or antigen negative, antibody positive Placenta Hominis for use is raw material, and Placenta Hominis is cut into small pieces, and multigelation 3～5 times adds an amount of double distilled water, and it is ground; Add sodium chloride solution again, making its concentration in placenta plasma is 0.9% (weight ratio), stirs evenly, and adds 36% formaldehyde in homogenate, and making homogenate include concentration of formaldehyde is 0.125% (volume ratio), puts 56 ℃ of water-bath 5-15 hours, and constantly stirs; Homogenate being got supernatant after centrifugal adjusts pH value with NaOH to adjust pH value is 6.8～7.0; It is interior more than 100 hours to be statically placed in 35 ℃ of-40 ℃ of incubators again; With aforesaid liquid filter, after the ultrafiltration anti-B-hepatitis placental specific transfer factor injection.
Raw material of the present invention is easy to get, and preparation technology is also not too complicated, unless experimental results show that outside the specific immune activity that hepatitis B virus is still had clear and definite specificity immuning activity, therapeutic effect is better, does not have any toxic agent reaction.
The invention will be further described below in conjunction with embodiment.
Take out hepatitis virus marker antigen negative, antibody positive Placenta Hominis, it is cleaned, be cut into fine grained chippings, multigelation 3 times; Place by (or in high speed bruisher) in the colloid mill, add Placenta Hominis equal weight double distilled water, grind (smashing to pieces) 3 times repeatedly; Add 3 times of placental weight 1.2% sodium chloride solutions, stir evenly, make sodium chloride-containing 0.9% (weight ratio) in the homogenate, the weight ratio of placenta tissue and water is 1: 4; Add 36% formaldehyde, making homogenate include concentration of formaldehyde is 0.125% (V/V), behind the mixing, puts 56 ℃ of water-baths 5 hours, and constantly stirring makes temperature even; Homogenate centrifugal 20 minutes through 3000VPM, taking out supernatant is 6.8～7.0 with NaOH adjustment PH, leaves standstill 35 ℃ of incubators interior 100 hours; Filter with Xi Shi filter, first 3 degerming plates then, the aseptic filtration of the acidproof filtration funnel of G6, molecular weight 10000 roads, reuse cross section and a ultrafilter membrane ultrafiltration, anti-B-hepatitis placental specific transfer factor injection.
Claims (1)
1. the preparation method of an anti-B-mode liver placental transfer factor injection, it is characterized in that: select for use hepatitis b virus marker antigen negative antibody positive Placenta Hominis to be the preparation raw material, its preparation method is made up of following steps:
A. get the Placenta Hominis of hepatitis b virus marker antigen negative antibody positive, it is cut into small pieces, multigelation 3～5 times;
B. in Placenta Hominis, add an amount of double distilled water, it is ground;
C. add sodium chloride solution, making the interior weight sodium chloride specific concentration of homogenate is 0.9%;
D. add 36% formaldehyde in homogenate, making homogenate include the formaldehyde volume by volume concentration is 0.125%;
E. homogenate was placed 56 ℃ of water-bath 5-15 hours, and constantly stir;
F. homogenate is centrifugal, getting supernatant after centrifugal, to adjust pH value with NaOH be 6.8～7.0;
G. aforesaid liquid is statically placed in 35 ℃ of-40 ℃ of incubators more than 100 hours;
H. aforesaid liquid is filtered and ultrafiltration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100357A CN1049119C (en) | 1993-01-19 | 1993-01-19 | Preparation method of anti-hepatitis B placental transfer factor injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93100357A CN1049119C (en) | 1993-01-19 | 1993-01-19 | Preparation method of anti-hepatitis B placental transfer factor injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1089843A CN1089843A (en) | 1994-07-27 |
| CN1049119C true CN1049119C (en) | 2000-02-09 |
Family
ID=4982972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93100357A Expired - Fee Related CN1049119C (en) | 1993-01-19 | 1993-01-19 | Preparation method of anti-hepatitis B placental transfer factor injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1049119C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299763C (en) * | 2003-07-31 | 2007-02-14 | 张光曙 | Method for preparing anti-hepatitis-B humanbody placenta transfer factor powder injecta |
| CN100406058C (en) * | 2006-04-28 | 2008-07-30 | 北京大学人民医院 | A kind of placenta factor and its preparation method and application |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103463131B (en) * | 2013-09-23 | 2015-09-30 | 河南牧翔动物药业有限公司 | A kind of preparation method of sheep placenta transfer factor solution |
| TWI672157B (en) * | 2016-11-06 | 2019-09-21 | 微邦科技股份有限公司 | Apparatus for pressurized liquid transfusion |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055486A (en) * | 1990-03-31 | 1991-10-23 | 王鸿鸣 | The preparation technology of activating agent for T cells breeding |
-
1993
- 1993-01-19 CN CN93100357A patent/CN1049119C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055486A (en) * | 1990-03-31 | 1991-10-23 | 王鸿鸣 | The preparation technology of activating agent for T cells breeding |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299763C (en) * | 2003-07-31 | 2007-02-14 | 张光曙 | Method for preparing anti-hepatitis-B humanbody placenta transfer factor powder injecta |
| CN100406058C (en) * | 2006-04-28 | 2008-07-30 | 北京大学人民医院 | A kind of placenta factor and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1089843A (en) | 1994-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0030444B1 (en) | A process for preparing substances having interferon inducing activity | |
| Mitchell et al. | Folic Acid. I. Concentration from Spinach1a | |
| US2328361A (en) | Method of conditioning sludge | |
| Jarrett et al. | Growth of feline leukaemia virus in human cells | |
| CN1049119C (en) | Preparation method of anti-hepatitis B placental transfer factor injection | |
| CN116617303B (en) | A kind of roxburghii functional ingredient composition and its preparation method and application | |
| CA1324084C (en) | Method of extracting a physiological active substance from the husks of pine nuts and anti-contagion medicine made of said extract as principal raw material | |
| DE3432714A1 (en) | TUMOR THERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF | |
| US4359415A (en) | Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine | |
| EP0018976A1 (en) | Medical protein hydrolysate and process of using the same | |
| RU2137486C1 (en) | Human placenta allogenic preparation showing anti-inflammatory, reparative, antibacterial, wound-healing effect and method of its preparing | |
| CN116179638B (en) | Preparation method of protamine polypeptide and product | |
| Green et al. | Survival of E. typhi in sewage treatment plant processes | |
| RU2001120513A (en) | METHOD FOR PRODUCING A MEDICINE "SKVAAKAN" | |
| CN108892358A (en) | A kind of high-efficiency composite biological flocculant and preparation method thereof for Treatment of Sludge | |
| US5241091A (en) | Method of extracting a physiological active substance from the husks of pine nuts and anti-contagion medicine made of said extract as principal raw material | |
| CN110054711A (en) | The extracting method of hyaluronic acid in a kind of umbilical cord | |
| JPS61200923A (en) | Substance having antiallergic action and production thereof | |
| CN1299763C (en) | Method for preparing anti-hepatitis-B humanbody placenta transfer factor powder injecta | |
| CN1059237C (en) | Method for producing recombined human liver cytokinin and its use for curing serious hepatic disease | |
| STEINBERG | A modified and improved method for the preparation of thymus extract | |
| CN116159078A (en) | Process for producing pig spleen transfer factor by using Shuanghuanglian powder and application | |
| CN106219700A (en) | A kind of purifying agent for polluted water for removing flocculate | |
| US260165A (en) | Henei collet | |
| CN1135894A (en) | Composition of stingray bone and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |